ACCOUNTS - Final Accounts preparation

Registered number: 03043815

OXFORD GENE TECHNOLOGY LIMITED

UNAUDITED

ANNUAL REPORT AND FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2025

OXFORD GENE TECHNOLOGY LIMITED

REGISTERED NUMBER: 03043815

STATEMENT OF FINANCIAL POSITION

AS AT 31 MARCH 2025

		2025		2024
Note		£		£


Current assets
Debtors: amounts falling due within one year	5	55,228,909		55,228,909
Cash at bank and in hand		10,820		10,820
		55,239,729		55,239,729
Creditors: amounts falling due within one year	6	(31,396,476)		(31,396,476)
Net current assets			23,843,253		23,843,253
Total assets less current liabilities			23,843,253		23,843,253



Net assets			23,843,253		23,843,253

Capital and reserves
Called up share capital	7	200	200
Profit and loss account		23,843,053	23,843,053
		23,843,253	23,843,253

The members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

G Williams

Director

Date: 26 November 2025

The notes on pages 3 to 6 form part of these financial statements.

Page 1

OXFORD GENE TECHNOLOGY LIMITED

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 MARCH 2025

	Called up share capital	Profit and loss account	Total equity
	£	£	£
At 1 April 2024	200	23,843,053	23,843,253
At 31 March 2025	200	23,843,053	23,843,253

The notes on pages 3 to 6 form part of these financial statements.

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 MARCH 2024

	Called up share capital	Profit and loss account	Total equity
	£	£	£
At 1 April 2023	200	23,843,053	23,843,253
At 31 March 2024	200	23,843,053	23,843,253

The notes on pages 3 to 6 form part of these financial statements.

Page 2

OXFORD GENE TECHNOLOGY LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

1.	General information

Oxford Gene Technology Limited ("the Company") is a private company limited by shares incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company’s registered office is shown on the company information page.

These financial statements are presented in pounds sterling because that is the currency of the primary environment in which the Company operates.

2.Accounting policies

2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 101 'Reduced Disclosure Framework' and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 101 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 3).

2.2

Financial Reporting Standard 101 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions under FRS 101:

∙the requirements of IFRS 7 Financial Instruments: Disclosures

∙the requirement in paragraph 38 of IAS 1 'Presentation of Financial Statements' to present comparative information in respect of:

- paragraph 79(a)(iv) of IAS 1;

∙the requirements of IAS 7 Statement of Cash Flows

∙the requirements of paragraph 17 and 18A of IAS 24 Related Party Disclosures

∙the requirements in IAS 24 Related Party Disclosures to disclose related party transactions entered into between two or more members of a group, provided that any subsidiary which is a party to the transaction is wholly owned by such a member

∙the requirements of paragraphs 130(f)(ii), 130(f)(iii), 134(d)-134(f) and 135(c)-135(e) of IAS 36 Impairment of Assets.

This information is included in the consolidated financial statements of Sysmex Corporation as at 31 March 2025 and these financial statements may be obtained from www.sysmex.co.jp/en/.

2.3

Going concern

The Company has received a letter of support from the ultimate controlling party, Sysmex Corporation, to provide any necessary support to enable the Company to meet its liabilities as they fall due for a period of at least 12 months from the date on which the financial statements are approved. Having considered the financial position of Sysmex Corporation, the directors are satisfied that it has sufficient resources to provide financial support should it be required.

In light of the support that the Company has from its ultimate controlling party, the directors believe the Company will have sufficient funds for the foreseeable future and as such these financial statements have been prepared on a going concern basis.

Page 3

OXFORD GENE TECHNOLOGY LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)

2.4

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of comprehensive income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.7

Creditors

Creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers.

Creditors are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method.

Page 4

OXFORD GENE TECHNOLOGY LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

3.	Judgements in applying accounting policies and key sources of estimation uncertainty

In the application of the Company's accounting policies, which are described in note 2, the directors are required to make judgements (other than those involving estimations) that have a significant impact on the amounts recognised and to make estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

There are no sources of material estimation uncertainty.

Critical judgments in applying the Company's accounting policies

Recoverability of amounts owed by group undertakings
Management make estimates when considering the recoverability of amounts owed by group undertakings and whether any provision is required based on expected monies to be received. The directors have assessed the position of each amounts owed by group undertakings and have not identified any impairment.

Employees

The Company has no employees other than the Directors, who did not receive any remuneration (2024 - £NIL).

Debtors

					2025	2024
					£	£


Amounts owed by group undertakings	55,228,909	55,228,909
	55,228,909	55,228,909

Amounts owed by the parent company and fellow subsidiaries are unsecured, interest free and repayable on demand. There are no other balances owed by related parties.

6.	Creditors: Amounts falling due within one year
		2025	2024
		£	£

Amounts owed to group undertakings	31,396,476	31,396,476
	31,396,476	31,396,476

The amounts owed to the parent company and other group undertakings are unsecured, repayable on demand and do not accrue interest.

Page 5

OXFORD GENE TECHNOLOGY LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

7.	Share capital
		2025	2024
		£	£

Allotted, called up and fully paid

200 (2024 - 200) Ordinary shares of £1.00 each	200	200

8.	Related party transactions
	The Company has taken advantage of the exemption within FRS 101, for wholly owned subsidiary undertakings not to disclose transactions within the same group. The consolidated financial statements for Sysmex Corporation, in which the Company is included, are publicly available at www.sysmex.co.jp/en/.

9.	Controlling party

The Company's immediate controlling party is Oxford Gene Technology IP Limited, incorporated in England and Wales.

In the opinion of the directors, the Company's ultimate parent Company and ultimate controlling party is Sysmex Corporation, a Company incorporated in Japan.

The parent undertaking of the largest and smallest group, which includes the Company and for which group accounts are prepared, is Sysmex Corporation, registered at 1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan. Copies of the group financial statements of Sysmex Corporation are available from the company website www.sysmex.co.jp/en/.

Page 6